Taylor C. Kress

Taylor C. Kress

Auto-generated profile, based on publicly available information

Taylor C. Kress

Medical College of Georgia, Augusta University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TNThiago Bruder do Nascimento
Thiago Bruder do Nascimento
TKTaylor C. Kress
Taylor C. Kress
SKSimone Kennard
Simone Kennard
ECEric J. Belin de Chantemèle
Eric J. Belin de Chantemèle
Background: Cardiovascular disease is currently the leading cause of death in patients with human immunodeficiency virus on combination antiretroviral therapy. Although the use of the protease inhibitor ritonavir has been associated with increased prevalence of cardiovascular disease, the underlying mechanisms remain ill‐defined. Herein, we tested the hypothesis that ritonavir‐mediated lipoatrophy causes endothelial dysfunction via reducing endothelial leptin signaling. Methods and Results: Long‐term (4 weeks) but not short‐term (3 days) treatment with ritonavir reduced body weight, fat mass, and leptin levels and induced endothelial dysfunction in mice. Moreover, ritonavir increased vascular NADPH oxidase 1, aortic H 2 O 2 levels as well as interleukin‐1β, GATA3 (GATA binding protein 3), the macrophage marker (F4/80), and C‐C chemokine receptor type 5 (CCR5) expression. Reactive oxygen species scavenging with tempol restored endothelial function, and both NADPH oxidase 1 and CCR5 deletion in mice protected from ritonavir‐mediated endothelial dysfunction and vascular inflammation. Remarkably, leptin infusion markedly improved endothelial function and significantly reduced vascular NADPH oxidase 1, interleukin‐1β, GATA3, F4/80, and CCR5 levels in ritonavir‐treated animals. Selective deficiency in endothelial leptin receptor abolished the protective effects of leptin infusion on endothelial function. Conversely, selective increases in endothelial leptin signaling with protein tyrosine phosphatase deletion blunted ritonavir‐induced endothelial dysfunction. Conclusions: All together, these data indicate that ritonavir‐associated endothelial dysfunction is a direct consequence of a reduction in adiposity and leptin secretion, which decreases endothelial leptin signaling and leads to a NADPH oxidase 1–induced, CCR5‐mediated reduction in NO bioavailability. These latter data also introduce leptin deficiency as an additional contributor to cardiovascular disease and leptin as a negative regulator of CCR5 expression, which may provide beneficial avenues for limiting human immunodeficiency virus infection.

16 October 2019 in F1000Research
Verified
Journal Article
Open access
PDF file
TNThiago Bruder do Nascimento
Thiago Bruder do Nascimento
TKTaylor C. Kress
Taylor C. Kress
ECEric J. Belin de Chantemèle
Eric J. Belin de Chantemèle
Lipodystrophy is a disease characterized by a partial or total absence of adipose tissue leading to severe metabolic derangements including marked insulin resistance, type 2 diabetes, hypertriglyceridemia, and steatohepatitis. Lipodystrophy is also a source of major cardiovascular disorders which, in addition to hepatic failure and infection, contribute to a significant reduction in life expectancy. Metreleptin, the synthetic analog of the adipocyte-derived hormone leptin and current therapy of choice for patients with lipodystrophy, successfully improves metabolic function. However, while leptin has been associated with hypertension, vascular diseases, and inflammation in the context of obesity, it remains unknown whether its daily administration could further impair cardiovascular function in patients with lipodystrophy. The goal of this short review is to describe the cardiovascular phenotype of patients with lipodystrophy, speculate on the etiology of the disorders, and discuss how the use of murine models of lipodystrophy could be beneficial to address the question of the contribution of leptin to lipodystrophy-associated cardiovascular disease.

19 November 2024 in Circulation
Verified
Journal Article
Closed access
SASuhib Alhusban
Suhib Alhusban
MNMohamed Nofal
Mohamed Nofal
AKAnita Kovacs-Kasa
Anita Kovacs-Kasa
TKTaylor C. Kress
Taylor C. Kress
MKM. Murat Koseoglu
M. Murat Koseoglu
BABrian H. Annex
Brian H. Annex
BACKGROUND: Endothelial cells (ECs) use glycolysis to produce energy. In preclinical models of peripheral arterial disease, further activation of EC glycolysis was ineffective or deleterious in promoting hypoxia-dependent angiogenesis, whereas pentose phosphate pathway activation was effective. Hexosamine biosynthesis pathway, pentose phosphate pathway, and glycolysis are closely linked. Glucosamine directly activates hexosamine biosynthesis pathway. METHODS: Hind-limb ischemia in endothelial nitric oxide synthase knockout (eNOS −/− ) and BALB/c mice was used. Glucosamine (600 μg/g per day) was injected intraperitoneally. Blood flow recovery was assessed using laser Doppler perfusion imaging and angiogenesis was studied by CD31 immunostaining. In vitro, human umbilical vein ECs and mouse microvascular ECs with glucosamine, L-glucose, or vascular endothelial growth factor (VEGF 165 a) were tested under hypoxia and serum starvation. Cell Counting Kit–8, tube formation, intracellular reactive oxygen species, electric cell–substrate impedance sensing, and fluorescein isothiocyanate dextran permeability were assessed. Glycolysis and oxidative phosphorylation were assessed by seahorse assay. Gene expression was assessed using RNA sequencing, real-time quantitative polymerase chain reaction, and Western blot. Human muscle biopsies from patients with peripheral arterial disease were assessed for EC O-GlcNAcylation before and after supervised exercise versus standard medical care. RESULTS: On day 3 after hind-limb ischemia, glucosamine-treated versus control eNOS −/− mice had less necrosis (n=4 or 5 per group). Beginning on day 7 after hind-limb ischemia, glucosamine-treated versus control BALB/c mice had higher blood flow, which persisted to day 21, when ischemic muscles showed greater CD31 staining per muscle fiber (n=8 per group). In vitro, glucosamine versus L-glucose ECs showed improved survival (n=6 per group) and tube formation (n=6 per group). RNA sequencing of glucosamine versus L-glucose ECs showed increased amino acid metabolism (n=3 per group). That resulted in increased oxidative phosphorylation (n=8–12 per group) and serine biosynthesis pathway without an increase in glycolysis or pentose phosphate pathway genes (n=6 per group). This was associated with better barrier function (n=6–8 per group) and less reactive oxygen species (n=7 or 8 per group) compared with activating glycolysis by VEGF 165 a. These effects were mediated by activating transcription factor 4, a driver of exercise-induced angiogenesis. In muscle biopsies from humans with peripheral arterial disease, EC/O-GlcNAcylation was increased by 12 weeks of supervised exercise versus standard medical care (n=6 per group). CONCLUSIONS: In cells, mice, and humans, activation of hexosamine biosynthesis pathway by glucosamine in peripheral arterial disease induces an “exercise-like” angiogenesis and offers a promising novel therapeutic pathway to treat this challenging disorder.

22 April 2025 in Circulation
Verified
Journal Article
Closed access
TKTaylor C. Kress
Taylor C. Kress
CBCandee T. Barris
Candee T. Barris
LKLaszlo Kovacs
Laszlo Kovacs
BKBeryl N. Khakina
Beryl N. Khakina
CJColeton R. Jordan
Coleton R. Jordan
ECEric J. Belin de Chantemèle
Eric J. Belin de Chantemèle
BACKGROUND: Although combination antiretroviral therapy has increased life expectancy in people living with HIV, it has led to a marked increase in the prevalence of hypertension, the cause of which is unknown. Despite combination antiretroviral therapy, HIV-derived proteins remain expressed and produced by CD4 + T lymphocytes in people living with HIV. However, their contribution to HIV-associated hypertension and impaired endothelium-dependent relaxation remains ill defined. METHODS: Here, we tested the hypothesis that CD4 + T cells expressing viral proteins contribute to endothelial dysfunction and hypertension using the Tg26 mouse model of HIV that expresses 7 of the 9 HIV proteins under the long terminal repeat promoter. We used male and female mice, bone marrow transplantation (BMT), adoptive transfer of CD4 + T cells, and aorta specimen discarded from people living with HIV. RESULTS: We reported that intact Tg26 mice and mice receiving BMT (Tg26→WT) or CD4 + T cells from Tg26 mice display impaired endothelium-dependent relaxation and hypertension. Conversely, BMT from WT mice into Tg26 mice, inhibition of T cell activation, and CD4 + T cell depletion restored endothelial function and blood pressure in Tg26 mice. Cytokine profiling revealed that Tg26 mice, Tg26→WT, and Tg26 CD4 + T cells consistently exhibit high interleukin 1α (IL-1α) levels with no significant increase in other cytokines, whereas BMT from WT mice into Tg26 mice reduced IL-1α levels. IL-1α neutralization reduced blood pressure and restored endothelial function in Tg26 mice. To investigate the role of CD4 + T cells and IL-1α in endothelial dysfunction, we developed an aorta-immune cell coculture system. Exposure of WT aortas to Tg26 CD4 + T cells impaired endothelium-dependent relaxation, which was blocked by IL-1α–neutralizing antibody. While investigating the mechanisms of endothelial dysfunction, we reported that Tg26 mice, Tg26→WT aorta exhibit high NADPH oxidase (NOX) 1 expression. IL-1α exposure increased NOX1 in human microvascular endothelial cells, and NOX1 blockade restored endothelial function in Tg26 and Tg26→WT arteries, whereas NOX1 deficiency protected against Tg26 BMT-induced impaired endothelium-dependent relaxation and hypertension. Aortas from people living with HIV exhibit high NOX1 levels, and exposure of human aorta to Tg26 T cells increased NOX1 expression. CONCLUSIONS: We provide the first evidence that CD4 + T cells expressing HIV viral proteins induced hypertension through IL-1α–mediated increases in vascular NOX1, which impairs endothelial function in males and females.

Verified
Journal Article
Open access
PDF file
TNThiago Bruder do Nascimento
Thiago Bruder do Nascimento
TKTaylor C. Kress
Taylor C. Kress
MPMatthew Pearson
Matthew Pearson
Weiqin ChenWeiqin Chen
Weiqin Chen
SKSimone Kennard
Simone Kennard
ECEric J. Belin de Chantemèle
Eric J. Belin de Chantemèle
The adipokine leptin, which is best-known for its role in the control of metabolic function, is also a master regulator of cardiovascular function. While leptin has been approved for the treatment of metabolic disorders in patients with congenital generalized lipodystrophy (CGL), the effects of chronic leptin deficiency and the treatment on vascular contractility remain unknown. Herein, we investigated the effects of leptin deficiency and treatment (0.3 mg/day/7 days) on aortic contractility in male Berardinelli-Seip 2 gene deficient mice (gBscl2-/-, model of CGL) and their wild-type control (gBscl2+/+), as well as in mice with selective deficiency in endothelial leptin receptor (LepREC-/-). Lipodystrophy selectively increased vascular adrenergic contractility via NO-independent mechanisms and induced hypertrophic vascular remodeling. Leptin treatment and Nox1 inhibition blunted adrenergic hypercontractility in gBscl2-/- mice, however, leptin failed to rescue vascular media thickness. Selective deficiency in endothelial leptin receptor did not alter baseline adrenergic contractility but abolished leptin-mediated reduction in adrenergic contractility, supporting the contribution of endothelium-dependent mechanisms. These data reveal a new direct role for endothelial leptin receptors in the control of vascular contractility and homeostasis, and present leptin as a safe therapy for the treatment of vascular disease in CGL.

1 September 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
LKLaszlo Kovacs
Laszlo Kovacs
TKTaylor C. Kress
Taylor C. Kress
AKAnita Kovacs-Kasa
Anita Kovacs-Kasa
RBRobin Brice
Robin Brice
SVSakshi Vanjani
Sakshi Vanjani
ECEric J. Belin de Chantemèle
Eric J. Belin de Chantemèle
Background: Thanks to the advent of combination antiretroviral therapy, life expectancy has noticeably increased in people with HIV; however, they also display an elevated susceptibility to developing severe pulmonary vascular disease. Despite efforts to understand the role of HIV‐encoded proteins in the pathogenesis of the disease, the underlying mechanisms remain to be elucidated. Methods: Using 3 mouse models of HIV and in vitro cell studies, we tested the hypothesis that HIV‐related proteins induce pulmonary vascular disease via Podnl1 (podocan‐like protein 1)‐dependent mechanisms. Results: We reported that the expression of HIV proteins in Tg26 mice and bone marrow transplant from Tg26 to wild‐type mice promotes the development of pulmonary vascular disease with no sex differences. RNAseq and quantitative polymerase chain reaction analysis revealed, for the first time, high expression of Podnl1 in the lungs of our HIV models. Strikingly, lung specimens from people with HIV on combination antiretroviral therapy exhibit higher Podnl1 levels compared with individuals without HIV. We also revealed that the observed cardiopulmonary alterations and expression levels of Podnl1 were more pronounced in aged intact Tg26 mice. In addition, Podnl1 overexpression resulted in increased collagen‐I production and pulmonary artery smooth muscle cells proliferation. Remarkably, we found that HIV‐Tat (transactivator of transcription) is the only viral protein detectable in peripheral blood mononuclear cells obtained from people with HIV on combination antiretroviral therapy, and chronic exposure of mice to HIV‐Tat recapitulated the cardiopulmonary complications of intact and bone marrow transplant Tg26 mice. Conclusions: We provide the first evidence that HIV‐Tat and Podnl1 are important contributing factors to pulmonary vascular disease related to HIV infection, which presents potential new therapeutic avenues for the prevention of HIV‐associated cardiopulmonary complications.